Statin use in acute coronary syndromes: Cellular mechanisms and clinical evidence

Current Opinion in Lipidology

Volumn 13, Issue 6, 2002, Pages 625-630

  Rosenson, Robert S ^a,b   Brown, Alan S ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Midwest Heart Foundation   (United States)

Author keywords

Acute coronary syndromes; Endothelial function; Inflammatory mediators; Statins; Unstable atherosclerotic plaque

Indexed keywords

AMYLOID A PROTEIN; ATORVASTATIN; C REACTIVE PROTEIN; COLLAGEN; CYTOKINE; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN RECEPTOR; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; THROMBOPLASTIN;

ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PROTECTION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS;

ACUTE DISEASE; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036909129     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200212000-00005     Document Type: Review

References (51)

1. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279:1643-1650.
2. Rosenson RS. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 2001; 1:411-420.
3. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89:36-44.
4. Boyle JJ. Association of coronary plaque rupture and atherosclerotic inflammation. J Pathol 1997; 191:93-99.
5. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90:1669-1678.
6. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25 (Suppl 2):S9-S12.
7. Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (± cholestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000; 86:1293-1298.
8. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285:1711-1718.
9. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36:1774-1780.
10. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285:430-436.
11. Rosenson RS. Statin therapy in acute cardiovascular syndromes: A new horizon. Cardiol Rev 1999; 16 (Suppl.):1-6.
12. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101:948-954.
13. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906.
14. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-2524.
15. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
16. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-493.
17. Aengevaeren WR, Uijen GJ, Jukema JW, et al. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1997; 96:429-435.
18. Eichstadt HW, Eskotter H, Hoffman I, et al. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76:122A-125A.
19. van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation 1996; 94:1503-1505.
20. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95:324-328.
21. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial. Circulation 1999; 99:3227-3233.
22. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metallo-proteinases and tissue factor in vivo and in vitro. Circulation 2001; 103:276-283.
23. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32:2057-2064.
24. Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147:253-261.
25. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31:684-691.
26. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001; 103:926-933.
27. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103:993-999.
28. Shiomi M, Ito T, Hirouchi Y, Enomoto M. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis 2001; 157:75-84.
29. Nissen SE. Rationale for a postintervention continuum of care: Insights from intravascular ultrasound. Am J Cardiol 2000; 86:12H-17H.
30. Cannon CP, McCabe CH, Belder R, et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 Trial. Am J Cardiol 2002; 89:860-861.
31. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1998; 353:983-984.
32. Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36:427-431.
33. Rosenson RS, Koenig W. High-sensitivity CRP and cardiovascular risk in CHD patients. Curr Opin Cardiol 2002; 17:325-331.
34. Ridker PM, Rifai N, Pfeffer MA et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230-235.
35. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103:1191-1193.
36. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933-1935.
37. Kinlay S, Rifai N, Libby P, Ganz P. Effect of atorvastatin on C-reactive protein in patients with acute coronary syndrome: A substudy of the MIRACL Trial. J Am Coll Cardiol 2002; 39 (Suppl A):304A.
38. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140:271-280.
39. Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17:265-272.
40. Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: Role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105:1756-1759.
41. Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290:434-438.
42. Corash L, Andersen J, Poindexter BJ, Schaefer EJ. Platelet function and survival in patients with severe hypercholesterolemia. Arteriosclerosis 1981; 1:443-448.
43. Nofer JR, Tepel M, Kehrel B, et al. Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation 1997; 95:1370-1377.
44. Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92:3172-3177.
45. Rosenson RS. Lipid lowering drugs and pheology. In: Gaw A, Shepherd J, eds. Lipids and atherosclerosis annual 2002. London: Martin Dunitz, Ltd; 2002: in press.
46. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332:635-641.
47. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001; 155:463-466.
48. Sacks FM, Pfeffer MA, Moyle LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
49. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
50. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105:1446-1452.
51. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol 2001; 87:819-822.